Camizestrant & ESR1: Improved Survival in Breast Cancer
Breakthrough findings demonstrate that switching to camizestrant upon detecting ESR1 mutations drastically improves the survival of patients battling advanced breast cancer. This pivotal phase 3 trial underscores the power of early intervention and the potential of cell-free DNA in revolutionizing treatment strategies. Patients experienced considerably extended progression-free survival when camizestrant was introduced after ESR1 mutations were identified,outperforming those who continued with their initial therapy. This research highlights a critical shift towards proactive treatment for ER-positive, HER2-negative advanced breast cancer. News Directory 3 brings you the latest advancements in oncology. As other SERDs emerge, clinical trials will reveal whether similar benefits are achievable. Discover what’s next in personalized breast cancer management.
Camizestrant Improves Survival in Advanced Breast Cancer, Trial Shows
Updated June 2, 2025
CHICAGO — Identifying ESR1 mutations during initial treatment for ER-positive, HER2-negative advanced breast cancer could pave the way for earlier intervention and improved survival, according to a phase 3 trial.
The study, presented at the ASCO Annual Meeting and published in The New England Journal of Medicine, found that patients who switched to camizestrant (AstraZeneca) after ESR1 mutations were detected experienced a median progression-free survival (PFS) about 7 months longer than those who remained on their original therapy. The research highlights the potential of cell-free DNA to measure tumor burden and tailor treatment strategies.
Dr. Eleonora Teplinsky, head of breast and gynecologic medical oncology at Valley-mount Sinai Thorough Cancer Care, called SERENA-6 an “incredible” study with significant implications. She emphasized the importance of early intervention in advanced breast cancer treatment.
according to Teplinsky, detecting disease progression via standard imaging frequently enough puts clinicians “behind.” Switching therapy early, before imaging reveals progression, allows doctors to “stay ahead of the curve.” Maintaining patients on first-line endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer is crucial because outcomes tend to worsen with subsequent treatments. Extending the duration of first-line endocrine therapy improves both survival and quality of life.
“When patients progress unscanned, we’re already behind,” Teplinsky said. “We’re switching therapy, and we’ve already lost control.An early switch approach before we see disease progression on imaging allows us to essentially stay ahead of the curve.”
A key question is whether other selective estrogen receptor degraders (serds) could replace camizestrant, which is not yet FDA approved.
“This is a question that everyone’s thinking about, but we don’t have that data,” Teplinsky said. “Not all oral SERDs are the same, and we don’t know if using the available oral SERDs in this setting is going to have the same results.This is realy going to evolve as we have this data.”
What’s next
further research is needed to determine if other SERDs can achieve similar results and to refine the use of cell-free DNA in monitoring and treating advanced breast cancer.